Focused On-demand Library for Ras-like protein family member 11B

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9BPW5

UPID:
RSLBB_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9BPW5; B2RC51; Q96KC5

BACKGROUND:
Ras-like protein family member 11B, with the unique identifier Q9BPW5, is part of the Ras protein superfamily. These proteins are integral to transmitting signals within cells, thereby influencing cell division, survival, and apoptosis. Despite its association with such vital cellular functions, the detailed role of Ras-like protein family member 11B in these processes is yet to be discovered.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ras-like protein family member 11B holds promise for unveiling new therapeutic avenues. Given its potential involvement in signaling pathways critical for cellular health, targeting this protein could lead to innovative treatments for conditions characterized by abnormal cell signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.